Skip to main content
Equibles
SLN logo

SLN · Silence Therapeutics plc

Track SLN — free

Use SLN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SLN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.61 -0.49 (-3.48%) At close · Aug 19
Market Cap
$1.98B
Shares
141.74M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.61 Open$14.59 Day$13.47–14.59 52W close$4.30–15.43 Avg vol 30d1.4M Short int1.8M · 1.3% float · 3.3d Short vol20% Last earningsFeb 27, 2025 DataSep 2020–Aug 2026 Filing10-Q · Aug 10

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +88%
above
Price vs 50-day avg +30%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +15%
trailing
6-month return +151%
trailing
YTD return +124%
this year
Relative strength +140%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.30% of float · ▲ +16.8% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
72 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Weak
Revenue growth −99%
Y/Y
Gross margin 62%
contracting
EPS growth −91%
Y/Y
Free cash flow $-62.3M
Balance sheet $11.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −42%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+88% Bullish
Price vs 50-day avg
+30% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.30% of float · ▲ +16.8% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
72 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $14 · 84% Range high $15
vs 200-day avg +88% vs 50-day avg +30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Total outstanding shares 141,739,180 Q2 FY2026 —
Weighted average shares outstanding (basic and diluted) 141,709,762 Q2 FY2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLN
Silence Therapeutics plc
this stock
$1.98B +123.8% -98.7% — 1.3%
ONC
BeOne Medicines Ltd.
 $535.83B +24.0% +22179.2% 823.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.88B +21.8% +46.2% 30.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.27B +8.9% +20.8% 20.3 3.3%
ARGX
Argenx SE
 $61.75B +22.8% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
72
% held
16.2%
Net QoQ
+2.9M sh
Top holder
Siren, L.L.C.
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
1.8M
Days to cover
3.3d
Change
+264.6K sh
View
Short Volume
Short vol %
20%
As of
Aug 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$12
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
52.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$559.0K
Net income (FY)
$-88.6M
EPS diluted
$-0.63
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
16
View
Exempt Offerings
Offering
$45.5M
Filed
Feb 18, 2021
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View
Investor Relations
Latest news
Silence Therapeutics Highlights F…
Published
Jun 11, 2026
View

Performance

5D 20D 120D MTD YTD
SLN +0.2% +15.1% +151.1% +29.7% +123.9%
SPY -0.4% +2.9% +11.6% +3.0% +12.8%
vs SPY +0.7% +12.2% +139.5% +26.8% +111.1%
Key facts CIK 1479615 CUSIP 82686Q101 13F (30d) 72 filings 72 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)